These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3754837)

  • 1. Effects of defibrotide on peripheral obliterative vascular diseases.
    Ulutin ON; Ilhan-Berkel N; Tunali H; Ozer M; Balkuv-Ulutin S; Onsel C; Urgancioğlu I
    Haemostasis; 1986; 16 Suppl 1():59-62. PubMed ID: 3754837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness of defibrotide in vaso-occlusive disorders and its mode of actions.
    Ulutin ON
    Semin Thromb Hemost; 1988; 14 Suppl():58-63. PubMed ID: 2848323
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of defibrotide on physical performance and hemorheologic picture in patients with peripheral arteriopathy.
    Marrapodi E; Leanza D; Giordano S; Nazzari M; Corsi C
    Clin Trials Metaanal; 1994 Apr; 29(1):21-30. PubMed ID: 10150182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical experience in patients with chronic peripheral obliterating arteriopathy: defibrotide versus definite molecular weight heparan sulfate (MW 7500-15000 dalton)].
    Michelini S; Micci A; Failla A; Grechi G; Iantaffi A
    Minerva Cardioangiol; 1996; 44(1-2):33-7. PubMed ID: 8767620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease.
    Strano A; Fareed J; Sabbá C; Albano O; Allegra C; Carlizza A; Binaghi F; Fronteddu F; Del Guercio R; Arpaia MR
    Semin Thromb Hemost; 1991; 17 Suppl 2():228-34. PubMed ID: 1948094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral and intravenous defibrotide on blood viscosity in patients with peripheral obliterative arterial disease.
    Belfiglio A; Traietti P; Bologna E; Salvo G
    Clin Ther; 1989; 11(4):479-84. PubMed ID: 2776165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defibrotide and peripheral obliterative arterial disease: preliminary data.
    Arosio E; Pancera P; Zannoni M; Arcaro G; Priante F; Lechi A
    Int J Clin Pharmacol Ther Toxicol; 1989 Nov; 27(11):526-9. PubMed ID: 2533180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of chronic obliterative arteriopathy of the legs in the second Fontaine's stage. Personal experience with a buflomedil-pentoxifylline-defibrotide combination].
    Marci M; Albiani B; Ricci M; Russo F
    Clin Ter; 1995 Mar; 146(3):211-4. PubMed ID: 7789083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot evaluation of the effect of defibrotide in patients affected by peripheral arterial occlusive disease.
    Sabbá C; Zupo V; Dina F; Nazzari M; Albano O
    Int J Clin Pharmacol Ther Toxicol; 1988 May; 26(5):249-52. PubMed ID: 3045026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of functional changes in arteriosclerotic chronic obliterating peripheral arterial diseases (COPA) and Buerger's and Raynaud's diseases with pharmacological sympathicolysis, with or without indirect surgical treatment].
    Bagliani A; Borri P; Taborelli R
    Minerva Cardioangiol; 1973 Jun; 21(6):439-52. PubMed ID: 4720185
    [No Abstract]   [Full Text] [Related]  

  • 11. Fibrinolytic effects of defibrotide in atherosclerotic patients.
    Patrassi GM; Sartori MT; Viero ML; Scapinello MP; Boeri G; Girolami A
    Semin Thromb Hemost; 1991; 17 Suppl 1():101-5. PubMed ID: 2068562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intra-arterial treatment of arterial obliterative disease (author's transl)].
    Mörl H
    Dtsch Med Wochenschr; 1974 Nov; 99(45):2284-6. PubMed ID: 4448136
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of intermittent claudication with defibrotide or mesoglycan. A double blind study.
    Laurora G; Ambrosoli L; Cesarone MR; De Sanctis MT; Incandela L; Marelli C; Belcaro G
    Panminerva Med; 1994 Jun; 36(2):83-6. PubMed ID: 7831064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experiences with the treatment of peripheral vascular diseases with Xavin].
    Brücknerová O
    Vnitr Lek; 1973 Apr; 19(4):379-86. PubMed ID: 4699159
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of defibrotide after oral and parenteral administration in patients with peripheral obliterative arterial disease (POAD).
    Craveri A; Tornaghi G; Ranieri R; Stanzani M; Landi G; Paganardi L; Passaretti B; Gallo E
    Int Angiol; 1990; 9(4):274-7. PubMed ID: 2099963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Defibrotide].
    Gava R
    G Clin Med; 1988 Mar; 69(3):229-31. PubMed ID: 3169453
    [No Abstract]   [Full Text] [Related]  

  • 17. A clinical trial with pyridinolcarbamate in the treatment of patients with obstructive diseases of the peripheral arteries.
    Zelikovsky A; Urca I; Shaklai M; de Vries A
    Jpn Heart J; 1973 Jan; 14(1):12-21. PubMed ID: 4541560
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypervolemic treatment of the chronic obliterative arteriopathies of extremities.
    Brassai Z; Koválszki P; Pop GH; Kiss K; Olosz E
    Med Interne; 1986; 24(1):37-41. PubMed ID: 2422732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defibrotide: properties and clinical use of an old/new drug.
    Pescador R; Capuzzi L; Mantovani M; Fulgenzi A; Ferrero ME
    Vascul Pharmacol; 2013; 59(1-2):1-10. PubMed ID: 23680861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinolytic enhancement in diabetic microangiopathy with defibrotide.
    Belcaro G; Marelli C; Pomante P; Laurora G; Cesarone MR; Ricci A; Girardello R; Barsotti A
    Angiology; 1992 Oct; 43(10):793-800. PubMed ID: 1476266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.